Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Cmc-Computers Materials & Continua ; 75(3):5717-5742, 2023.
Artículo en Inglés | Web of Science | ID: covidwho-20232208

RESUMEN

Coronavirus has infected more than 753 million people, ranging in severity from one person to another, where more than six million infected people died worldwide. Computer-aided diagnostic (CAD) with artificial intelligence (AI) showed outstanding performance in effectively diagnosing this virus in real-time. Computed tomography is a complementary diagnostic tool to clarify the damage of COVID-19 in the lungs even before symptoms appear in patients. This paper conducts a systematic literature review of deep learning methods for classifying the segmentation of COVID-19 infection in the lungs. We used the methodology of systematic reviews and meta-analyses (PRISMA) flow method. This research aims to systematically analyze the supervised deep learning methods, open resource datasets, data augmentation methods, and loss functions used for various segment shapes of COVID-19 infection from computerized tomography (CT) chest images. We have selected 56 primary studies relevant to the topic of the paper. We have compared different aspects of the algorithms used to segment infected areas in the CT images. Limitations to deep learning in the segmentation of infected areas still need to be developed to predict smaller regions of infection at the beginning of their appearance.

2.
Alternative Therapies in Health and Medicine ; 26:72-78, 2020.
Artículo en Inglés | Web of Science | ID: covidwho-1070315

RESUMEN

Context . RNA viruses exhibit an extraordinary ability to evolve in a changing environment and to switch from animal hosts to humans. The ongoing COVID-19 pandemic, recognized as a respiratory disease, is an example of zoonotic transmission of the RNA virus known as SARS-CoV-2. The development and regulatory approval of a vaccine against SARS-CoV-2 pose multiple preventive and therapeutic challenges, especially during an ongoing pandemic. Objective . The review intended to examine the challenges and recent achievements in the development of vaccine candidates against COVID-19. Design . The research team performed a literature review, searching relevant and up to date information from the literature. The sources of data included Google Scholar, PubMed, NCBI, and Yahoo. The search terms used were COVID-19 challenges, SARS-CoV-2 prospective challenges, RNA viruses adoptability, host switching by RNA viruses, COVID-19 vaccines. Setting . The study took place at the digital libraries of contributing institutions. The data was combined, selected for further analysis and manuscript preparation at King Abdulaziz University. Results . RNA viruses with high rate of genome alterations and evolution have better chances to survive in the adverse environmental conditions by adopting the alternate host species. The recent epidemics such as SARS, MERS, and COVID-19 are examples of zoonotic transmission of RNA viruses from animal species to the humans. However, the mechanisms involved in the switching-on to new host species need further investigations to control the zoonotic transmissions in near future. As of April 2020, 115 candidate vaccines were being evaluated;78 of them had been found to be active, and a few of them are in Phase I trials. In the development of different types of vaccine candidates against COVID19, multiple international pharmaceutical and biotechnology companies are involved. Conclusions . Emerging and re-emerging pathogenic RNA viruses pose a serious threat to human health. Little is known about the human-host adoptive mechanism for zoonotic transmission. Deep insights into the molecular mechanism responsible for the switching of animal or bird viruses to humans could provide target molecules or events to prevent such transmissions in the near future. Fast development and approval of efficacious and safe vaccines is key to the effort to provide preventive measures against COVID-19 and future viruses. However, the development and availability of a vaccine candidate is a time-consuming process and often can't be completed during an epidemic. Currently, several types of vaccines are under development, and most of them won't realistically be available in time for the present COVID-19 pandemic.

3.
Alternative therapies in health and medicine ; 2020.
Artículo en Inglés | MEDLINE | ID: covidwho-740735

RESUMEN

Context: RNA viruses exhibit an extraordinary ability to evolve in a changing environment and to switch from animal hosts to humans. The ongoing COVID-19 pandemic, recognized as a respiratory disease, is an example of zoonotic transmission of the RNA virus known as SARS-CoV-2. The development and regulatory approval of a vaccine against SARS-CoV-2 pose multiple preventive and therapeutic challenges, especially during an ongoing pandemic. Objective: The review intended to examine the challenges and recent achievements in the development of vaccine candidates against COVID-19. Design: The research team performed a literature review, searching relevant and up to date information from the literature. The sources of data included Google Scholar, PubMed, NCBI, and Yahoo. The search terms used were COVID-19 challenges, SARS-CoV-2 prospective challenges, RNA viruses adoptability, host switching by RNA viruses, COVID-19 vaccines. Setting: The study took place at the digital libraries of contributing institutions. The data was combined, selected for further analysis and manuscript preparation at King Abdulaziz University. Results: RNA viruses with high rate of genome alterations and evolution have better chances to survive in the adverse environmental conditions by adopting the alternate host species. The recent epidemics such as SARS, MERS, and COVID-19 are examples of zoonotic transmission of RNA viruses from animal species to the humans. However, the mechanisms involved in the switching-on to new host species need further investigations to control the zoonotic transmissions in near future. As of April 2020, 115 candidate vaccines were being evaluated;78 of them had been found to be active, and a few of them are in Phase I trials. In the development of different types of vaccine candidates against COVID-19, multiple international pharmaceutical and biotechnology companies are involved. Conclusions: Emerging and re-emerging pathogenic RNA viruses pose a serious threat to human health. Little is known about the human-host adoptive mechanism for zoonotic transmission. Deep insights into the molecular mechanism responsible for the switching of animal or bird viruses to humans could provide target molecules or events to prevent such transmissions in the near future. Fast development and approval of efficacious and safe vaccines is key to the effort to provide preventive measures against COVID-19 and future viruses. However, the development and availability of a vaccine candidate is a time-consuming process and often can't be completed during an epidemic. Currently, several types of vaccines are under development, and most of them won't realistically be available in time for the present COVID-19 pandemic.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA